EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy

Hohyung Nam, Soon-Hee Jung, Jii Bum Lee, Jee Hyun Kong, Seungtaek Lim iD

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.15522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Hohyung Nam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, Catholic University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Membrane Proteins, Lung Neoplasms, Intracellular Signaling Peptides and Proteins. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Small cell lung cancer (SCLC) is known for its high proliferative rate and poor prognosis. Although Delta‐like ligand 3 (DLL3) is specifically expressed on the surface of SCLC, the association of DLL3 with prognosis in SCLC remains uncertain. Hence, we aimed to evaluate prognostic role of DLL3 in extensive stage of SCLC treated with first‐line chemotherapy. Materials and Methods A total of 54 patients with extensive stage of SCLC (ES‐SCLC) who were treated with first‐line chemotherapy were included for our analysis. In addition, tissue specimen should be available for immuno‐histochemical staining for DLL3, and their clinico‐pathologic data, including progression‐free survival (PFS) and overall survival (OS), were obtained. DLL3 expression and the percentage of tumor cells with DLL3 positive among total cancer cells were analyzed microscopically and DLL3 high and DLL3 low were defined as the percentage of DLL3 positive tumor cells versus total cancer cells ≧ 75% and < 75%, respectively.

Results

DLL3 expression was not associated with any of the clinico‐pathological characteristics such as age at diagnosis, sex, response to first‐line chemotherapy, second‐line chemotherapy (Yes or No), and number of metastatic sites. However, response to first‐line chemotherapy and number of metastatic sites were correlated to PFS, while DLL3 expression and number of metastatic sites were correlated to OS.

Conclusion

DLL3 was highly expressed in SCLC, and not associated with any clinico‐pathological characteristics. In survival outcome, DLL3 was correlated with worse OS, which suggests the prognostic role of DLL3 in ES‐SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaMembrane ProteinsLung NeoplasmsIntracellular Signaling Peptides and ProteinsBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemalePrognosisMiddle AgedAgedNeoplasm StagingAdult

Stichwörter der Autor:innen

DLL3 proteinhumanprognosissmall cell lung carcinoma

Substanzen

DLL3 protein, humanMembrane ProteinsIntracellular Signaling Peptides and ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, Catholic University, Seoul, Republic of Korea.
  • Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Hematology-Oncology, Division of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
  • Center of Evidence-Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, Republic of Korea.

ORCID-Profile: Seungtaek Lim

Zitieren

APA

Nam, H., Jung, S. H., Lee, J. B., Kong, J. H., & Lim, S. (2025). Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15522

Vancouver

Nam H, Jung SH, Lee JB, Kong JH, Lim S. Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy. Thoracic Cancer. 2025. doi:10.1111/1759-7714.15522

BibTeX
@article{Nam2025,
  author = {Nam, Hohyung and Jung, Soon-Hee and Lee, Jii Bum and Kong, Jee Hyun and Lim, Seungtaek},
  title = {Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.15522}
}
Kostenlos starten →